XENCO INC
XENCO INC
Aktie · US98401F1057 · XNCR · A1W96L (XNMS)
Übersicht Finanzkennzahlen
9,19 USD
-1,29 % -0,12 USD
NASDAQ/NMS (GLOBAL MARKET) (XNAS) · Aktuelle Kurse und Charts bei MoneyPeak
13.06.2025 20:00

Aktuelle Kurse von XENCO INC

BörseTickerWährungLetzter UmsatzKursTagesveränderung
XNAS: NASDAQ
NASDAQ
XNCR
USD
13.06.2025 20:00
9,19 USD
9,43 USD
-2,55 %

Performance

Heute Woche Monat 3 Monate 6 Monate 1 Jahr 5 Jahre
0,00 % -5,26 % 12,90 % -27,98 % -61,76 % -55,34 % -67,67 %

Firmenprofil zu XENCO INC Aktie

Xencor, Inc., a clinical stage biopharmaceutical company, focuses on the discovery and development of engineered monoclonal antibody and cytokine therapeutics to treat patients with cancer and autoimmune diseases. The company provides Sotrovimab that targets the SARS-CoV-2 virus; Ultomiris for the treatment of patients with paroxysmal nocturnal hemoglobinuria and atypical hemolytic uremic syndrome; and Monjuvi for the treatment of patients with relapsed or refractory diffuse large B-cell lymphoma. It develops Plamotamab, a tumor-targeted antibody, which is in Phase I clinical trial to treat non-Hodgkin lymphoma; Vudalimab, a bispecific antibody, which is in Phase II clinical trial to treat metastatic castration-resistant prostate cancer and other solid tumor types; and Tidutamab that is in Phase II clinical trial to treat neuroendocrine tumors. The company is also developing XmAb306, which is in Phase I clinical trial to treat solid tumors; XmAb104 and XmAb841, which are in Phase I clinical trial to treat patients with selected solid tumors; XmAb564 that is in Phase I clinical trial to treat autoimmune diseases; AMG 509, which is in Phase I clinical trial to treat prostate cancer; XmAb819 for patients with renal cell carcinoma; and Novartis XmAb. It develops VIR-3434, which is in Phase II clinical trial for patients with hepatitis B virus infection; VIR-2482 that is in Phase 1/2 clinical trial to trat influenza A; VIR-7832, which is in Phase 1b/2a trial to treat mild-to-moderate COVID-19; and BMS-986414 + BMS-986413 is in Phase 2/3 NIH ACTIV-2 trial in treating COVID-19. The company develops AIMab7195 to reduce blood serum levels of IgE that mediates allergic responses and allergic disease; Obexelimab to treat autoimmune disease; and Xpro1595 to treat patients with Alzheimer's disease, mild cognitive impairment, and depression. It has a license agreement with Caris Life Sciences. Xencor, Inc. was incorporated in 1997 and is headquartered in Monrovia, California.

Investierte Fonds

Folgende Fonds haben in investiert: XENCO INC investiert:

Fonds
iShares Nasdaq US Biotechnology UCITS ETF USD (Dist)
Vol. in Mio
64,85
Anteil (%)
0,15 %

Unternehmensdaten

Name XENCO INC
Firma Xencor, Inc.
Symbol XNCR
Website https://www.xencor.com
Heimatbörse XNMS NASDAQ/NMS (GLOBAL MARKET)
WKN A1W96L
ISIN US98401F1057
Wertpapierart Aktie
Sektor Healthcare
Branche Biotechnology
CEO Dr. Bassil I. Dahiyat Ph.D.
Marktkapitalisierung 669 Mio
Land Vereinigte Staaten von Amerika
Währung USD
Mitarbeiter 0,3 T
Adresse 111 West Lemon Avenue, 91016 Monrovia
IPO Datum 2013-12-03

Ticker Symbole

Name Symbol
Frankfurt XE9.F
NASDAQ XNCR

Weitere Aktien

Investoren die XENCO INC die halten, haben auch folgende Aktien im Depot:
ADTRAN HOLDINGS INC
ADTRAN HOLDINGS INC Aktie
AMGEN INC
AMGEN INC Aktie
AUTODESK INC
AUTODESK INC Aktie
CISCO SYSTEMS INC
CISCO SYSTEMS INC Aktie
COSTCO WHOLESALE CORP
COSTCO WHOLESALE CORP Aktie
HELMA EIGENHEIMBAU AG
HELMA EIGENHEIMBAU AG Aktie
INTEL CORP
INTEL CORP Aktie
LAM RESEARCH CORP
LAM RESEARCH CORP Aktie
MICROSOFT CORP
MICROSOFT CORP Aktie
MONSTER BEVERAGE CORP
MONSTER BEVERAGE CORP Aktie
PSI SOFTWARE AG
PSI SOFTWARE AG Aktie
STHN CAL.GAS 25/55
STHN CAL.GAS 25/55 Anleihe
WALGREENS BOOTS ALLIANCE INC
WALGREENS BOOTS ALLIANCE INC Aktie
WITR COM.SEC.Z06/UN.IDX
WITR COM.SEC.Z06/UN.IDX ETC
Die Finanzplattform MoneyPeak trackt und analysiert Investitionen und Portfolios. Vom Wertpapier-Depot bis zum Crypto-Kauf.
Nützlich, simpel und kostenlos. Aktien, ETF, ETC, ETN, Indizes, Fonds, Anleihen, Zertifikate, Währungen, Optionen, Bezugsrechte.
Impressum Datenschutz Blog Community Feedback Changelog
Im App Store herunterladen Bei Google Play herunterladen
All rights reserved © LCP GmbH 2025